Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.61 USD | -2.12% | +3.37% | -8.18% |
05:57pm | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
05-15 | Transcript : Abeona Therapeutics Inc., Q1 2024 Earnings Call, May 15, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.18% | 187M | |
+33.68% | 49.46B | |
+1.56% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.69% | 26.61B | |
-21.04% | 18.64B | |
+7.39% | 13.16B | |
+28.64% | 12.55B | |
+23.85% | 12.1B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- Abeona Therapeutics to Submit Biologics License Application for Epidermolysis Bullosa Treatment Following Meeting with FDA